MY173378A - Efficient lipid delivery to human tear film using a salt-sensitive emulsion system - Google Patents

Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Info

Publication number
MY173378A
MY173378A MYPI2014001672A MYPI2014001672A MY173378A MY 173378 A MY173378 A MY 173378A MY PI2014001672 A MYPI2014001672 A MY PI2014001672A MY PI2014001672 A MYPI2014001672 A MY PI2014001672A MY 173378 A MY173378 A MY 173378A
Authority
MY
Malaysia
Prior art keywords
salt
tear film
sensitive emulsion
emulsion system
human tear
Prior art date
Application number
MYPI2014001672A
Other languages
English (en)
Inventor
Joseph G Vehige
Peter A Simmons
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY173378(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MY173378A publication Critical patent/MY173378A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2014001672A 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system MY173378A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161568089P 2011-12-07 2011-12-07
US201261625401P 2012-04-17 2012-04-17

Publications (1)

Publication Number Publication Date
MY173378A true MY173378A (en) 2020-01-21

Family

ID=47459152

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014001672A MY173378A (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Country Status (27)

Country Link
US (2) US9314528B2 (https=)
EP (5) EP3666257A1 (https=)
JP (1) JP6142419B2 (https=)
KR (1) KR102017922B1 (https=)
CN (2) CN104114152A (https=)
AR (1) AR089123A1 (https=)
AU (2) AU2012347459A1 (https=)
BR (1) BR112014013820A8 (https=)
CA (1) CA2858574C (https=)
CL (1) CL2014001518A1 (https=)
CO (1) CO6990739A2 (https=)
DK (2) DK2787968T3 (https=)
ES (2) ES2896336T3 (https=)
HU (2) HUE057140T2 (https=)
IL (1) IL233008A (https=)
IN (1) IN2014CN04809A (https=)
MX (1) MX355216B (https=)
MY (1) MY173378A (https=)
PH (2) PH12014501296B1 (https=)
PL (2) PL2787969T3 (https=)
PT (2) PT2787968T (https=)
RU (1) RU2014127074A (https=)
SG (1) SG11201403013VA (https=)
SI (2) SI2787968T1 (https=)
TW (1) TWI652072B (https=)
WO (2) WO2013086449A1 (https=)
ZA (1) ZA201404228B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
EP3266446B1 (en) 2016-07-07 2018-11-21 Laboratorios SALVAT, S.A. Ophthalmic composition comprising castor oil and medium chain triglyceride
US11903986B2 (en) 2016-08-19 2024-02-20 Akrivista Llc Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
CN114376961A (zh) 2017-08-18 2022-04-22 阿克里维斯塔有限责任公司 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物
AU2019261437B2 (en) 2018-04-27 2024-11-07 Allergan, Inc. Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
ATE6466T1 (de) * 1979-10-26 1984-03-15 Smith And Nephew Associated Companies P.L.C. Autoklavierbare emulsionen.
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
DE436726T1 (de) 1989-08-03 1992-02-06 Eisai Co., Ltd., Tokio/Tokyo Verfahren zur photostabilisierung von augenspuelloesungen sowie photostabilisierte augenspuelloesung.
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
EP0778021A4 (en) 1994-09-14 1998-06-03 Taisho Pharmaceutical Co Ltd DROPS TO CARE FOR THE CORNEA
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
AU1295200A (en) 1998-11-13 2000-06-05 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
JP2000159659A (ja) * 1998-11-30 2000-06-13 Kazuo Tsubota 眼科用人工涙液
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
CA2416169C (en) 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
WO2002038161A1 (en) 2000-11-08 2002-05-16 Bio-Concept Laboratories Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
AU2003301263A1 (en) * 2002-10-18 2004-05-04 Joel S. Echols Three layer tear formulation
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
JPWO2004084877A1 (ja) 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
AU2004249137B2 (en) * 2003-06-13 2010-03-11 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
EP1683528A4 (en) * 2003-11-10 2011-07-27 Toray Industries POLYSACCHARIDE-CONTAINING COMPOSITION AND OPHTHALMIC SOLUTION FOR STABILIZING THE TISSUE FILM
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
CN101668511A (zh) * 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
US8496976B2 (en) 2009-06-05 2013-07-30 Allergan, Inc. Artificial tears and therapeutic uses
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye

Also Published As

Publication number Publication date
DK2787968T3 (da) 2020-06-02
HK1203057A1 (en) 2015-10-16
IL233008A (en) 2017-07-31
CN104114152A (zh) 2014-10-22
EP4403220A2 (en) 2024-07-24
BR112014013820A2 (pt) 2017-06-13
IL233008A0 (en) 2014-07-31
EP2787969A1 (en) 2014-10-15
WO2013086438A1 (en) 2013-06-13
US20130197083A1 (en) 2013-08-01
ES2896336T3 (es) 2022-02-24
CL2014001518A1 (es) 2014-10-24
EP3666257A1 (en) 2020-06-17
CA2858574A1 (en) 2013-06-13
EP3981387A1 (en) 2022-04-13
PL2787968T3 (pl) 2020-08-24
CO6990739A2 (es) 2014-07-10
PH12014501296B1 (en) 2023-04-05
PH12014501296A1 (en) 2014-10-08
CN108969482A (zh) 2018-12-11
ZA201404228B (en) 2015-12-23
AU2017265181B2 (en) 2019-06-20
CA2858574C (en) 2017-05-30
KR20140107383A (ko) 2014-09-04
AR089123A1 (es) 2014-07-30
RU2018119362A3 (https=) 2021-09-07
SI2787968T1 (sl) 2020-08-31
HUE049489T2 (hu) 2020-09-28
PT2787968T (pt) 2020-06-16
EP2787969B1 (en) 2021-09-29
AU2017265181A1 (en) 2017-12-14
HUE057140T2 (hu) 2022-04-28
US9314528B2 (en) 2016-04-19
RU2014127074A (ru) 2016-02-10
KR102017922B1 (ko) 2019-09-03
AU2012347459A1 (en) 2014-07-03
IN2014CN04809A (https=) 2015-09-18
ES2797650T3 (es) 2020-12-03
SI2787969T1 (sl) 2021-12-31
TWI652072B (zh) 2019-03-01
US20130150324A1 (en) 2013-06-13
PT2787969T (pt) 2021-11-09
WO2013086449A1 (en) 2013-06-13
MX355216B (es) 2018-04-10
EP2787968A1 (en) 2014-10-15
HK1201458A1 (en) 2015-09-04
SG11201403013VA (en) 2014-07-30
EP2787968B1 (en) 2020-03-04
DK2787969T3 (da) 2021-11-01
TW201325633A (zh) 2013-07-01
MX2014006804A (es) 2014-09-22
PL2787969T3 (pl) 2021-12-20
JP2015504860A (ja) 2015-02-16
JP6142419B2 (ja) 2017-06-07
PH12021553172A1 (en) 2024-05-27
EP4403220A3 (en) 2024-10-23
RU2018119362A (ru) 2018-11-08
BR112014013820A8 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
MY173378A (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
IL260585B (en) Compositions and methods for treating retinal diseases
MY171920A (en) Prevention and treatment of ocular conditions
MY175997A (en) Antl-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
PH12018500401B1 (en) Antibodies specific for tgf-beta
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
MY183449A (en) Formulations of quinones for the treatment of ophthalmic diseases
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
NZ702169A (en) The use of heat shock protein 90 (hsp90) modulators for the treatment of metabolic syndrome
MX2009009839A (es) Formulaciones farmaceuticas a base de lipidos apolares y polares para uso oftalmico.
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112014001118A2 (pt) combinação tópica para aplicação oftálmica e uso de bimatoprost e brimonidina
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
CY1124538T1 (el) Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης
NZ607103A (en) A water-in-oil type emulsion for treating a disease of the eye
EP2656837A4 (en) LIPID NANOPARTICLES FOR THE TREATMENT OF EYE DISEASES
IN2014MN01551A (https=)
MX2015001804A (es) Metodos y composiciones para el tratamiento de condiciones relacionadas con la falta del suministro de sangre, choque y lesiones neuronales.
UA111645C2 (uk) Ефективна доставка ліпідів у слізну плівку людини з використанням чутливої до солі емульсійної системи
WO2012105854A3 (en) Compositions for administration to the eye
PL398967A1 (pl) Zastosowanie kwasu loganowego w terapii jaskry
UA93098C2 (en) Liposomal antihelminth agent based on fenasal
CL2010000695A1 (es) Composicion oftalmica acuosa que comprende una ciclosporina,glicerina y agua, donde la composicion contiene menos de 0,3% de cloruro de sodio y menos de 0,04% de metabisulfito de sodio; y uso para tratar una condicion ocular.
UA55466U (ru) Способ лечения метаболических нарушений у больных с контузионной травмой глаза